NASDAQ, TSX: NVCN
VANCOUVER, July 16, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN) announced today that, in connection with its new final short form base shelf prospectus (the "Base Shelf Prospectus") filed with securities regulatory authorities in the provinces of British Columbia,
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
A copy of the Registration Statement, including the related prospectus, or the Prospectus Supplement may be obtained by submitting a request to Chris Clark, Chief Financial Officer, at Neovasc's address at 5138-13562 Maycrest Way, Richmond, British Columbia, Canada, V6V 2J7. Copies of the Base Shelf Prospectus and Prospectus Supplement are available on SEDAR at www.sedar.com. Copies of the Registration Statement can be found on the SEC website at www.sec.gov.
About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc ReducerTM (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the TiaraTM (the "Tiara"), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe.
View original content:http://www.prnewswire.com/news-releases/neovasc-announces-filing-of-administrative-prospectus-supplement-relating-to-expiry-of-prior-shelf-prospectus--registration-statement-300680996.html
SOURCE Neovasc Inc.
Subscribe to our Free Newsletters!